These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10638597)

  • 1. Tamoxifen-induced transient multifocal hepatic fatty infiltration.
    Cai Q; Bensen M; Greene R; Kirchner J
    Am J Gastroenterol; 2000 Jan; 95(1):277-9. PubMed ID: 10638597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis.
    Murata Y; Ogawa Y; Saibara T; Nishioka A; Takeuchi N; Kariya S; Onishi S; Yoshida S
    Oncol Rep; 2003; 10(1):97-100. PubMed ID: 12469151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen-induced fatty liver in patients with breast cancer.
    Ogawa Y; Murata Y; Nishioka A; Inomata T; Yoshida S
    Lancet; 1998 Mar; 351(9104):725. PubMed ID: 9504521
    [No Abstract]   [Full Text] [Related]  

  • 4. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
    Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S
    Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic steatohepatitis.
    Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
    Lancet; 1999 Oct; 354(9186):1299-300. PubMed ID: 10520659
    [No Abstract]   [Full Text] [Related]  

  • 6. Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen.
    Nemoto Y; Saibara T; Ogawa Y; Zhang T; Xu N; Ono M; Akisawa N; Iwasaki S; Maeda T; Onishi S
    Intern Med; 2002 May; 41(5):345-50. PubMed ID: 12058881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy.
    Nishino M; Hayakawa K; Nakamura Y; Morimoto T; Mukaihara S
    AJR Am J Roentgenol; 2003 Jan; 180(1):129-34. PubMed ID: 12490491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients.
    Ohnishi T; Ogawa Y; Saibara T; Nishioka A; Kariya S; Fukumoto M; Onishi S; Yoshida S
    Oncol Rep; 2005 Mar; 13(3):485-9. PubMed ID: 15706422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen].
    Dray X; Tainturier MH; De La Lande P; Marty O; Mallet L
    Gastroenterol Clin Biol; 2000 Nov; 24(11):1122-3. PubMed ID: 11139682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients.
    Murata Y; Ogawa Y; Saibara T; Nishioka A; Fujiwara Y; Fukumoto M; Inomata T; Enzan H; Onishi S; Yoshida S
    Oncol Rep; 2000; 7(6):1299-304. PubMed ID: 11032933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer.
    Akhondi-Meybodi M; Mortazavy-Zadah MR; Hashemian Z; Moaiedi M
    Arab J Gastroenterol; 2011 Mar; 12(1):34-6. PubMed ID: 21429453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum leptin levels are associated with tamoxifen-induced hepatic steatosis.
    Günel N; Coşkun U; Toruner FB; Sancak B; Yilmaz E; Cengiz O; Elbeg S; Uner A; Ozkan S
    Curr Med Res Opin; 2003; 19(1):47-50. PubMed ID: 12661780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cirrhosis with steatohepatitis after adjuvant tamoxifen.
    Oien KA; Moffat D; Curry GW; Dickson J; Habeshaw T; Mills PR; MacSween RN
    Lancet; 1999 Jan; 353(9146):36-7. PubMed ID: 10023952
    [No Abstract]   [Full Text] [Related]  

  • 14. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis.
    Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H
    Lancet; 1999 May; 353(9166):1802. PubMed ID: 10348023
    [No Abstract]   [Full Text] [Related]  

  • 15. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
    Bruno S; Maisonneuve P; Castellana P; Rotmensz N; Rossi S; Maggioni M; Persico M; Colombo A; Monasterolo F; Casadei-Giunchi D; Desiderio F; Stroffolini T; Sacchini V; Decensi A; Veronesi U
    BMJ; 2005 Apr; 330(7497):932. PubMed ID: 15746106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen in early breast cancer.
    Saibara T; Ogawa Y; Onishi S
    Lancet; 1998 Aug; 352(9125):404. PubMed ID: 9717954
    [No Abstract]   [Full Text] [Related]  

  • 17. Tamoxifen-induced hepatotoxicity.
    Ahbeddou N; Belbaraka R; Fetohi M; Errihani H
    Indian J Cancer; 2011; 48(3):385. PubMed ID: 21921356
    [No Abstract]   [Full Text] [Related]  

  • 18. [A case of steatohepatitis associated with tamoxifen].
    Kanda T; Yokosuka O; Chiba T; Kojima H; Fukai K; Imazeki F; Saisho H
    Nihon Shokakibyo Gakkai Zasshi; 2002 Sep; 99(9):1119-21. PubMed ID: 12355903
    [No Abstract]   [Full Text] [Related]  

  • 19. Crystalline maculopathy: a rare complication of tamoxifen therapy.
    Srikantia N; Mukesh S; Krishnaswamy M
    J Cancer Res Ther; 2010; 6(3):313-5. PubMed ID: 21119261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen-induced fatty liver disease in a Caucasian patient.
    Eechoute K; Mathijssen RHJ; van Gelder T
    Breast Cancer Res Treat; 2018 Aug; 171(1):243-244. PubMed ID: 29736740
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.